gdc-0973 and Ovarian-Neoplasms

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but often lethal cancer that is diagnosed at a median age of 24 years. Optimal management of patients is not well defined, and current treatment remains challenging, necessitating the discovery of novel therapeutic approaches. The identification of SMARCA4-inactivating mutations invariably characterizing this type of cancer provided insights facilitating diagnostic and therapeutic measures against this disease. We show here that the BET inhibitor OTX015 acts in synergy with the MEK inhibitor cobimetinib to repress the proliferation of SCCOHT

Topics: Animals; Azetidines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epigenesis, Genetic; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nucleotides; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; S Phase; Xenograft Model Antitumor Assays